Advisor Partners’s Meridian Bioscience Inc VIVO Stock Holding History

Advisor Partners’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$599K	Buy	19,702 +145	+0.7%	+$3.92K	0.04%	427
2022 Q1	$508K	Buy	19,557 +81	+0.4%	+$1.93K	0.03%	505
2021 Q4	$398K	Buy	19,476 +309	+2%	+$5.92K	0.02%	583
2021 Q3	$369K	Sell	19,167 -3,219	-14%	-$64.2K	0.02%	570
2021 Q2	$497K	Buy	22,386 +103	+0.5%	+$2.19K	0.03%	508
2021 Q1	$585K	Buy	22,283 +295	+1%	+$7.01K	0.04%	437
2020 Q4	$411K	Buy	21,988 +293	+1%	+$5.47K	0.03%	507
2020 Q3	$368K	Sell	21,695 -945	-4%	-$18.4K	0.03%	474
2020 Q2	$527K	Buy	22,640 +4,787	+27%	+$69.4K	0.05%	356
2020 Q1	$149K	Buy	+17,853	New	+$150K	0.02%	565

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VLKIM

Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return

Advisor Partners's VIVO Position: Q2 2022 in Review

Advisor Partners increased its Meridian Bioscience Inc (VIVO) stake by 0.74% in Q2 2022, buying an estimated $3.92K and bringing the position to 19,702 shares worth $599K. The position accounts for 0.04% of the portfolio, ranked #427.

Advisor Partners first reported a position in VIVO in Q1 2020 and has held it in 10 quarters since. 216 funds tracked by Wall St. Rank hold VIVO as of Q2 2022.

Advisor Partners held 19,702 shares of Meridian Bioscience Inc worth $599K as of Q2 2022.
Advisor Partners bought 145 Meridian Bioscience Inc shares in Q2 2022, an estimated $3.92K.
Meridian Bioscience Inc made up 0.04% of Advisor Partners's portfolio in Q2 2022, its #427 holding.
Advisor Partners first reported a position in Meridian Bioscience Inc in Q1 2020 and has held it in 10 quarters since.
216 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2022.

Based on Advisor Partners's 13F filing for Q2 2022, filed 11 Aug 2022.